scholarly journals Using The Cancer Genome Atlas as an Inquiry Tool in the Undergraduate Classroom

2020 ◽  
Vol 11 ◽  
Author(s):  
William Hankey ◽  
Nicholas Zanghi ◽  
Mackenzie M. Crow ◽  
Whitney H. Dow ◽  
Austin Kratz ◽  
...  

Undergraduate students in the biomedical sciences are often interested in future health-focused careers. This presents opportunities for instructors in genetics, molecular biology, and cancer biology to capture their attention using lab experiences built around clinically relevant data. As biomedical science in general becomes increasingly dependent on high-throughput data, well-established scientific databases such as The Cancer Genome Atlas (TCGA) have become publicly available tools for medically relevant inquiry. The best feature of this database is that it bridges the molecular features of cancer to human clinical outcomes—allowing students to see a direct connection between the molecular sciences and their future professions. We have developed and tested a learning module that leverages the power of TCGA datasets to engage students to use the data to generate and test hypotheses and to apply statistical tests to evaluate significance.

2020 ◽  
Author(s):  
William Hankey ◽  
Nicholas Zanghi ◽  
Mackenzie Crow ◽  
Whitney Dow ◽  
Austin Kratz ◽  
...  

Undergraduate students in the biomedical sciences are often interested in future health-focused careers. This presents opportunities for instructors in genetics, molecular biology and cancer biology to capture their attention using lab experiences built around clinically relevant data. As biomedical science in general becomes increasingly dependent on high-throughput data, well-established scientific databases such as TCGA have become publicly available tools for medically relevant inquiry. The best feature of this database is that it bridges the molecular features of cancer to human clinical outcomes, allowing students to see a direct connection between the molecular sciences and their future professions. We have developed and tested a learning module that leverages the power of TCGA datasets to engage students to use the data to generate and test hypotheses and to apply statistical tests to evaluate significance. (Peer reviewed/published version: https://www.frontiersin.org/articles/10.3389/fgene.2020.573992/full)


JAMA Oncology ◽  
2017 ◽  
Vol 3 (12) ◽  
pp. 1654 ◽  
Author(s):  
Dezheng Huo ◽  
Hai Hu ◽  
Suhn K. Rhie ◽  
Eric R. Gamazon ◽  
Andrew D. Cherniack ◽  
...  

2016 ◽  
Vol 195 (4S) ◽  
Author(s):  
Daniel Lee ◽  
David Golombos ◽  
Padraic O'Malley ◽  
Deli Liu ◽  
Andrea Sboner ◽  
...  

Endocrine ◽  
2020 ◽  
Author(s):  
Anello Marcello Poma ◽  
Elisabetta Macerola ◽  
Liborio Torregrossa ◽  
Rossella Elisei ◽  
Ferruccio Santini ◽  
...  

Abstract Purpose The 8th edition of the American Joint Committee on Cancer (AJCC) staging led to a significant downstaging of well differentiated thyroid cancer patients. However, some patients who had been downstaged still experienced death. By using data from the thyroid cancer dataset of The Cancer Genome Atlas (TCGA), we aimed to find molecular features that could improve survival prediction. Methods TCGA data were downloaded from cBioPortal. Restaging of cases was performed according to the pathological reports. Results Out of 496 cases, 204 (41.1%) were downstaged, and the proportion of deaths increased in stages III and IV. TERT promoter mutations were no longer enriched in stage IV only, but significantly redistributed also in stages II and III. TERT mutation was the only alteration predictive of poor survival; however, in this series it was not independent from the AJCC staging. Five proteins (4E-BP1_pT70, Chk1_pS345, Snail, STAT5 alpha and PAI-1) were significantly associated with survival, and their use as a panel refined the risk stratification independently from the AJCC staging, with a hazard ratio for a positive result of 21.2 (95%CI 3.7–122.2, P = 0.0006). Conclusions In the TCGA series, the proportion of deaths is in line with the expected survival of the latest AJCC staging, with a neat separation of risk among stages. Nevertheless, the use of protein expression can be useful in refining the stratification. Finally, after the restaging, a considerable number of tumors with TERT mutations will be allocated in lower stages; hence, dedicated studies should define the prognostic usefulness of these mutations in low-stage diseases.


2019 ◽  
Author(s):  
Roozbeh Dehghannasiri ◽  
Donald Eric Freeman ◽  
Milos Jordanski ◽  
Gillian L. Hsieh ◽  
Ana Damljanovic ◽  
...  

Short AbstractThe extent to which gene fusions function as drivers of cancer remains a critical open question. Current algorithms do not sufficiently identify false-positive fusions arising during library preparation, sequencing, and alignment. Here, we introduce a new algorithm, DEEPEST, that uses statistical modeling to minimize false-positives while increasing the sensitivity of fusion detection. In 9,946 tumor RNA-sequencing datasets from The Cancer Genome Atlas (TCGA) across 33 tumor types, DEEPEST identifies 31,007 fusions, 30% more than identified by other methods, while calling ten-fold fewer false-positive fusions in non-transformed human tissues. We leverage the increased precision of DEEPEST to discover new cancer biology. For example, 888 new candidate oncogenes are identified based on over-representation in DEEPEST-Fusion calls, and 1,078 previously unreported fusions involving long intergenic noncoding RNAs partners, demonstrating a previously unappreciated prevalence and potential for function. Specific protein domains are enriched in DEEPEST calls, demonstrating a global selection for fusion functionality: kinase domains are nearly 2-fold more enriched in DEEPEST calls than expected by chance, as are domains involved in (anaerobic) metabolism and DNA binding. DEEPEST also reveals a high enrichment for fusions involving known and novel oncogenes in diseases including ovarian cancer, which has had minimal treatment advances in recent decades, finding that more than 50% of tumors harbor gene fusions predicted to be oncogenic. The statistical algorithms, population-level analytic framework, and the biological conclusions of DEEPEST call for increased attention to gene fusions as drivers of cancer and for future research into using fusions for targeted therapy.SignificanceGene fusions are tumor-specific genomic aberrations and are among the most powerful biomarkers and drug targets in translational cancer biology. The advent of RNA-Seq technologies over the past decade has provided a unique opportunity for detecting novel fusions via deploying computational algorithms on public sequencing databases. Yet, precise fusion detection algorithms are still out of reach. We develop DEEPEST, a highly specific and efficient statistical pipeline specially designed for mining massive sequencing databases, and apply it to all 33 tumor types and 10,500 samples in The Cancer Genome Atlas database. We systematically profile the landscape of detected fusions via employing classic statistical models and identify several signatures of selection for fusions in tumors.Software availabilityDEEPEST-Fusion workflow with a detailed readme file is available as a Github repository:https://github.com/salzmanlab/DEEPEST-Fusion. In addition to the main workflow, which is based on CWL, example input and batch scripts (for job submission on local clusters), and codes for building the SBT files and SBT querying are provided in the repository. All custom scripts used for systematic analysis of fusions are also available in the same repository.


2017 ◽  
pp. 1-12
Author(s):  
Manish R. Sharma ◽  
James T. Auman ◽  
Nirali M. Patel ◽  
Juneko E. Grilley-Olson ◽  
Xiaobei Zhao ◽  
...  

Purpose A 73-year-old woman with metastatic colon cancer experienced a complete response to chemotherapy with dose-intensified irinotecan that has been durable for 5 years. We sequenced her tumor and germ line DNA and looked for similar patterns in publicly available genomic data from patients with colorectal cancer. Patients and Methods Tumor DNA was obtained from a biopsy before therapy, and germ line DNA was obtained from blood. Tumor and germline DNA were sequenced using a commercial panel with approximately 250 genes. Whole-genome amplification and exome sequencing were performed for POLE and POLD1. A POLD1 mutation was confirmed by Sanger sequencing. The somatic mutation and clinical annotation data files from the colon (n = 461) and rectal (n = 171) adenocarcinoma data sets were downloaded from The Cancer Genome Atlas data portal and analyzed for patterns of mutations and clinical outcomes in patients with POLE- and/or POLD1-mutated tumors. Results The pattern of alterations included APC biallelic inactivation and microsatellite instability high (MSI-H) phenotype, with somatic inactivation of MLH1 and hypermutation (estimated mutation rate > 200 per megabase). The extremely high mutation rate led us to investigate additional mechanisms for hypermutation, including loss of function of POLE. POLE was unaltered, but a related gene not typically associated with somatic mutation in colon cancer, POLD1, had a somatic mutation c.2171G>A [p.Gly724Glu]. Additionally, we noted that the high mutation rate was largely composed of dinucleotide deletions. A similar pattern of hypermutation (dinucleotide deletions, POLD1 mutations, MSI-H) was found in tumors from The Cancer Genome Atlas. Conclusion POLD1 mutation with associated MSI-H and hyper-indel–hypermutated cancer genome characterizes a previously unrecognized variant of colon cancer that was found in this patient with an exceptional response to chemotherapy.


2018 ◽  
Vol Volume 11 ◽  
pp. 1-11 ◽  
Author(s):  
Chundi Gao ◽  
Huayao Li ◽  
Jing Zhuang ◽  
HongXiu Zhang ◽  
Kejia Wang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document